Cocrystal Pharma Extends Enrollment for Influenza Study

Cocrystal Pharma ( (COCP) ) has provided an announcement.

Cocrystal Pharma announced an extension of enrollment in its Phase 2a human challenge study for the investigational oral influenza PB2 inhibitor, CDI-42344, due to low influenza infection rates among participants. Despite these challenges, the company remains optimistic about the drug’s potential as a leading antiviral treatment for influenza, citing its safety profile and unique mechanism of action. The company is working on a protocol amendment to ensure sufficient infection rates, which is crucial for evaluating the drug’s antiviral effectiveness.

More about Cocrystal Pharma

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that focuses on discovering and developing novel antiviral therapeutics targeting the replication process of influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses. Utilizing unique structure-based technologies and Nobel Prize-winning expertise, the company aims to create first- and best-in-class antiviral drugs.

YTD Price Performance: 88.73%

Average Trading Volume: 30,560

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $33.06M

See more insights into COCP stock on TipRanks’ Stock Analysis page.